Child's Nervous System

, Volume 35, Issue 6, pp 1013–1020 | Cite as

Role of early and aggressive post-operative radiation therapy in improving outcome for pediatric central nervous system atypical teratoid/rhabdoid tumor

  • Wan-Chin Yang
  • Hsiu-Ju Yen
  • Muh-Lii Liang
  • Hsin-Hung Chen
  • Yi-Yen Lee
  • Tai-Tong Wong
  • Yu-Wen Hu
  • Yi-Wei ChenEmail author
Original Article



The purpose of the study is to evaluate possible prognostic factors and optimal management for pediatric atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system (CNS).


Twenty-eight pediatric patients with CNS AT/RT who were treated with radiation therapy (RT) as part of multimodality treatment regimens at a single institution (1996–2015) were reviewed. Survival outcomes were analyzed in relation to possible prognostic factors.


The 28 patients analyzed were followed up for a median 48-month period. Median progression-free survival (PFS) was 11 months, and overall survival (OS) was 57 months. Patients < 3 years old had RT delayed for a longer period after surgery (p = 0.04), and the mean RT dose to tumor bed was lower (p < 0.01) than in patients ≥ 3 years old. In multivariate analysis, a higher primary tumor bed RT dose was identified as a favorable prognostic factor for both PFS (hazard ratio [HR] = 0.85 per gray, p < 0.01) and OS (HR = 0.92 per gray, p = 0.02). In addition, an interval between surgery and RT initiation > 2 months, with disease progression observed before RT, as compared with an interval ≤ 2 months without disease progression prior to RT, was associated with worse PFS (HR = 8.50, p < 0.01) and OS (HR = 5.27, p < 0.01).


Early and aggressive RT after surgery is critical for successful disease control in AT/RT patients. Conversely, a delay in RT until disease progression is observed that leads to unfavorable outcomes.


High-dose chemotherapy Radiation dose Radiation therapy Time interval 



We would like to thank Taipei Veterans General Hospital pediatric CNS tumor group for assistance in this study.


No funding was received for this study.

Compliance with ethical standards

The study was conducted in accordance with the Declaration of Helsinki.

Ethical approval

The data of this study was extracted from database of pediatric brain tumors in Taipei Veterans General Hospital, and the study protocol was approved by the Institutional Review Board of the Taipei Veterans General Hospital. The IRB number is 97-07-05A.

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent to this study was obtained from the parents of all participants.

Supplementary material

381_2019_4126_MOESM1_ESM.pdf (425 kb)
ESM 1 (PDF 424 kb)


  1. 1.
    Athale UH, Duckworth J, Odame I, Barr R (2009) Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J Pediatr Hematol Oncol 31:651–663. CrossRefGoogle Scholar
  2. 2.
    Bartelheim K, Nemes K, Seeringer A, Kerl K, Buechner J, Boos J, Graf N, Durken M, Gerss J, Hasselblatt M, Kortmann RD, Teichert von Luettichau I, Nagel I, Nygaard R, Oyen F, Quiroga E, Schlegel PG, Schmid I, Schneppenheim R, Siebert R, Solano-Paez P, Timmermann B, Warmuth-Metz M, Fruhwald MC (2016) Improved 6-year overall survival in AT/RTS—results of the registry study Rhabdoid 2007. Cancer Med 5:1765–1775. CrossRefGoogle Scholar
  3. 3.
    Biegel JA (2006) Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus 20:E11CrossRefGoogle Scholar
  4. 4.
    Burger PC, Yu IT, Tihan T, Friedman HS, Strother DR, Kepner JL, Duffner PK, Kun LE, Perlman EJ (1998) Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol 22:1083–1092CrossRefGoogle Scholar
  5. 5.
    Buscariollo DL, Park HS, Roberts KB, Yu JB (2012) Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer 118:4212–4219. CrossRefGoogle Scholar
  6. 6.
    Chen YW, Wong TT, Ho DM, Huang PI, Chang KP, Shiau CY, Yen SH (2006) Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience). Int J Radiat Oncol Biol Phys 64:1038–1043. CrossRefGoogle Scholar
  7. 7.
    Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley PE, Bowers DC, Bendel A, Rubin J, Turner CD, Marcus KJ, Goumnerova L, Ullrich NJ, Kieran MW (2009) Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 27:385–389. CrossRefGoogle Scholar
  8. 8.
    Christopherson KM, Rotondo RL, Bradley JA, Pincus DW, Wynn TT, Fort JA, Morris CG, Mendenhall NP, Marcus RB Jr, Indelicato DJ (2014) Late toxicity following craniospinal radiation for early-stage medulloblastoma. Acta Oncol (Stockh) 53:471–480. CrossRefGoogle Scholar
  9. 9.
    DiPatri AJ Jr, Sredni ST, Grahovac G, Tomita T (2015) Atypical teratoid rhabdoid tumors of the posterior fossa in children. Childs Nerv Syst 31:1717–1728. CrossRefGoogle Scholar
  10. 10.
    Fossey M, Li H, Afzal S, Carret AS, Eisenstat DD, Fleming A, Hukin J, Hawkins C, Jabado N, Johnston D, Brown T, Larouche V, Scheinemann K, Strother D, Wilson B, Zelcer S, Huang A, Bouffet E, Lafay-Cousin L (2017) Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. J Neuro-Oncol 132:155–162. CrossRefGoogle Scholar
  11. 11.
    Haberler C, Laggner U, Slavc I, Czech T, Ambros IM, Ambros PF, Budka H, Hainfellner JA (2006) Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol 30:1462–1468. CrossRefGoogle Scholar
  12. 12.
    Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW, Walter AW, Rorke LB, Biegel JA (2004) Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 22:2877–2884. CrossRefGoogle Scholar
  13. 13.
    Ho DM, Hsu CY, Wong TT, Ting LT, Chiang H (2000) Atypical teratoid/rhabdoid tumor of the central nervous system: a comparative study with primitive neuroectodermal tumor/medulloblastoma. Acta Neuropathol 99:482–488CrossRefGoogle Scholar
  14. 14.
    Lafay-Cousin L, Hawkins C, Carret AS, Johnston D, Zelcer S, Wilson B, Jabado N, Scheinemann K, Eisenstat D, Fryer C, Fleming A, Mpofu C, Larouche V, Strother D, Bouffet E, Huang A (2012) Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. Eur J Cancer 48:353–359. CrossRefGoogle Scholar
  15. 15.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. CrossRefGoogle Scholar
  16. 16.
    Pai Panandiker AS, Merchant TE, Beltran C, Wu S, Sharma S, Boop FA, Jenkins JJ, Helton KJ, Wright KD, Broniscer A, Kun LE, Gajjar A (2012) Sequencing of local therapy affects the pattern of treatment failure and survival in children with atypical teratoid rhabdoid tumors of the central nervous system. Int J Radiat Oncol Biol Phys 82:1756–1763. CrossRefGoogle Scholar
  17. 17.
    Perez-Martinez A, Lassaletta A, Gonzalez-Vicent M, Sevilla J, Diaz MA, Madero L (2005) High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neuro-Oncol 71:33–38. CrossRefGoogle Scholar
  18. 18.
    Reddickaij WE, Russell JM, Glass JO, Xiong X, Mulhern RK, Langston JW, Merchant TE, Kun LE, Gajjar A (2000) Subtle white matter volume differences in children treated for medulloblastoma with conventional or reduced dose craniospinal irradiation. Magn Reson Imaging 18:787–793. CrossRefGoogle Scholar
  19. 19.
    Schrey D, Carceller Lechon F, Malietzis G, Moreno L, Dufour C, Chi S, Lafay-Cousin L, von Hoff K, Athanasiou T, Marshall LV, Zacharoulis S (2016) Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature. J Neuro-Oncol 126:81–90. CrossRefGoogle Scholar
  20. 20.
    Slavc I, Chocholous M, Leiss U, Haberler C, Peyrl A, Azizi AA, Dieckmann K, Woehrer A, Peters C, Widhalm G, Dorfer C, Czech T (2014) Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna experience 1992-2012. Cancer Med 3:91–100. CrossRefGoogle Scholar
  21. 21.
    Suissa S (2008) Immortal time bias in pharmacoepidemiology. Am J Epidemiol 167:492–499. CrossRefGoogle Scholar
  22. 22.
    Sung KW, Lim DH, Yi ES, Choi YB, Lee JW, Yoo KH, Koo HH, Kim JH, Suh YL, Joung YS, Shin HJ (2016) Tandem high-dose chemotherapy and autologous stem cell transplantation for atypical teratoid/rhabdoid tumor. Cancer Res Treat 48:1408–1419. CrossRefGoogle Scholar
  23. 23.
    Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, Krasin M, Dalton J, Hale G, Kun LE, Wallace D, Gilbertson RJ, Gajjar A (2005) Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 23:1491–1499. CrossRefGoogle Scholar
  24. 24.
    Verma V, Johnson CP, Bennion NR, Bhirud AR, Li S, McComb RD, Lin C (2015) Atypical teratoid rhabdoid tumor: long-term survival after chemoradiotherapy. Childs Nerv Syst 31:1393–1399. CrossRefGoogle Scholar
  25. 25.
    von Hoff K, Hinkes B, Dannenmann-Stern E, von Bueren AO, Warmuth-Metz M, Soerensen N, Emser A, Zwiener I, Schlegel PG, Kuehl J, Fruhwald MC, Kortmann RD, Pietsch T, Rutkowski S (2011) Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT/RT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database. Pediatr Blood Cancer 57:978–985. CrossRefGoogle Scholar
  26. 26.
    Zaky W, Dhall G, Ji L, Haley K, Allen J, Atlas M, Bertolone S, Cornelius A, Gardner S, Patel R, Pradhan K, Shen V, Thompson S, Torkildson J, Sposto R, Finlay JL (2014) Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience. Pediatr Blood Cancer 61:95–101. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Radiation Oncology, Department of OncologyTaipei Veterans General HospitalTaipeiRepublic of China
  2. 2.National Yang-Ming University School of MedicineTaipeiRepublic of China
  3. 3.Division of Pediatric Hematology and Oncology, Department of PediatricsTaipei Veterans General HospitalTaipeiRepublic of China
  4. 4.Division of Pediatric Neurosurgery, The Neurological InstituteTaipei Veterans General HospitalTaipeiRepublic of China
  5. 5.Department of NeurosurgeryTaipei Medical University Hospital, Taipei Medical UniversityTaipeiRepublic of China

Personalised recommendations